NICE approves dual therapy for EGFR-mutant lung cancer

Credit: Getty Images/Marcin Klapczynski

By Olivia Bowthorpe

People in England with advanced non-small cell lung cancer caused by a specific gene mutation will soon have access to a new treatment plan.

The combination of two drugs, amivantamab and lazertinib, can be used as a first treatment for patients with mutations in the EGFR gene, following a decision by NICE.